Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma
暂无分享,去创建一个
Yunyun Xu | Z. Zeng | Zhen Zhang | Qi Zhao | Yafen Ye | Aolin Shen | Fan Chen
[1] Ruixia Wang,et al. CD73 facilitates invadopodia formation and boosts malignancy of head and neck squamous cell carcinoma via the MAPK signaling pathway , 2022, Cancer science.
[2] Ming Yan,et al. CD73 in small extracellular vesicles derived from HNSCC defines tumour‐associated immunosuppression mediated by macrophages in the microenvironment , 2022, Journal of extracellular vesicles.
[3] Qi Zhang,et al. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. , 2022, Seminars in cancer biology.
[4] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[5] G. Jin,et al. Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells , 2021, Nature Biomedical Engineering.
[6] Xiaochen Bo,et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.
[7] C. Supuran,et al. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present) , 2021, Expert opinion on therapeutic patents.
[8] Zhiyu Qian,et al. Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer. , 2021, Molecular pharmaceutics.
[9] C. R. Leemans,et al. Head and neck squamous cell carcinoma , 2020, Nature Reviews Disease Primers.
[10] Fan Zhang,et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment , 2020, bioRxiv.
[11] Bin Zhang,et al. Targeting CD73 to augment cancer immunotherapy. , 2020, Current opinion in pharmacology.
[12] L. Buisseret,et al. The adenosine pathway in immuno-oncology , 2020, Nature Reviews Clinical Oncology.
[13] G. Dubyak,et al. CD8+CD73+ T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue , 2020, European journal of immunology.
[14] Huidong Shi,et al. CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint , 2020, Nature Communications.
[15] Hung-Ming Wang,et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.
[16] S. Karam,et al. Radioimmunotherapy for the treatment of head and neck cancer. , 2019, The Lancet. Oncology.
[17] Yong Wan,et al. CD73: an emerging checkpoint for cancer immunotherapy. , 2019, Immunotherapy.
[18] M. Stratton,et al. Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis , 2019, Cell.
[19] Wei Liu,et al. CancerSEA: a cancer single-cell state atlas , 2018, Nucleic Acids Res..
[20] Yassen Assenov,et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.
[21] G. Freeman,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[22] A. Kulkarni,et al. Specific blockade CD73 alters the “exhausted” phenotype of T cells in head and neck squamous cell carcinoma , 2018, International journal of cancer.
[23] Anh Nhat Tran,et al. HPAanalyze: an R package that facilitates the retrieval and analysis of the Human Protein Atlas data , 2018, BMC Bioinformatics.
[24] L. Emens,et al. Targeting adenosine for cancer immunotherapy , 2018, Journal of Immunotherapy for Cancer.
[25] M. Smyth,et al. Targeting immunosuppressive adenosine in cancer , 2017, Nature Reviews Cancer.
[26] S. Robson,et al. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets , 2017, Immunological reviews.
[27] R. Bourgon,et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.
[28] P. Laurent-Puig,et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.
[29] Bin Zhu,et al. Edinburgh Research Explorer Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors , 2022 .
[30] J. Mesirov,et al. The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .
[31] C. Swanton,et al. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. , 2015, Cancer discovery.
[32] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[33] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[34] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[35] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[36] Guangchuang Yu,et al. clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.
[37] C. Cole,et al. COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.
[38] A. McKenna,et al. The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.
[39] Shicai Wang,et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer , 2018, Nucleic Acids Res..
[40] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[41] Renaud Gaujoux,et al. A flexible R package for nonnegative matrix factorization , 2010, BMC Bioinformatics.
[42] Erik K. Malm,et al. A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics* , 2005, Molecular & Cellular Proteomics.